Skip Navigation

European Heart Journal 1991 12(5):639-641;
Copyright © 1991 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by IBÁÑEZ, L.
Right arrow Articles by LAPORTE, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by IBÁÑEZ, L.
Right arrow Articles by LAPORTE, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 The European Society of Cardiology

Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach

L. IBÁÑEZ, J. JUAN, E. PÉREZ, X. CARNÉ and J. R. LAPORTE

Servei de Farmacologia Clinica CS Vall d'Hebron, Barcelona, Spain

accepted 2 July 1990.

Correspondence: Prof Joan-Ramon Laporte, Servei de Farmacologia Clinica, CS vall d'Hebron, 08035 Barcelona, Spain

Abstract

The risk of agranulocytosis associated with anti-arrhythmic drugs has been assessed by studying previous drug exposure of all cases collected through a muiticentre surveillance network in a defined geographical area during the period 1980–1988. One hundred and eighty-one patients with agranulocytosis (<500 granulocytes mm–3 at least in two different blood counts) were interviewed with a structured questionnaire. Eight cases attributable to anti-arrhythmic drugs were identified, all of them related to aprindine. Data on the consumption of several anti-arrhythmic drugs (amiodarone, aprindine, quinidine, propafenone) were obtained in order to estimate the risk of agranulocytosis related with the previous use of these drugs. A relevant risk was identjfied only for aprindine, of the order of two cases per 1000 patient-years. Our data suggest that the risk of agranulocytosis associated with aprindine is lower than previously found.

Key Words: Agranulocytosis • aprindine • anti-arrhythmic drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
L. Ibanez, X. Vidal, E. Ballarin, and J.-R. Laporte
Population-Based Drug-Induced Agranulocytosis
Arch Intern Med, April 25, 2005; 165(8): 869 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. M. van der Klauw, R. Goudsmit, M. R. Halie, M. B. van't Veer, R. M. C. Herings, J. H. P. Wilson, and B. H. Ch. Stricker
A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis
Arch Intern Med, February 22, 1999; 159(4): 369 - 374.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.